Takeda’s biologics license application for Dengue vaccine candidate (TAK-003) granted priority review by US FDA

Takeda

23 November 2022 - TAK-003 is being evaluated for the prevention of Dengue disease caused by any Dengue virus serotype in individuals 4 years through 60 years of age.

Takeda today announced that the US FDA has accepted and granted priority review of the biologics license application for TAK-003, the company’s investigational dengue vaccine candidate.

Read Takeda press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Vaccine , Priority review